ArticleBiomedical engineering online2016
Multi-scale mathematical modelling of tumour growth and microenvironments in anti-angiogenic therapy.
Article in Biomedical engineering online, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 18 citations in OpenAlex.
- GPU-accelerated volumetric-mosaic optical-resolution photoacoustic microscopy and quantifying tumor vasculature growth.Photoacoustics · 2025Article
- Biomechanics of flail chest injuries: tidal volume and respiratory work changes in multiple segmental rib fractures.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2025Article
- AMBER: A Modular Model for Tumor Growth, Vasculature and Radiation Response.Bulletin of mathematical biology · 2024Article
- Multiscale modeling of collective cell migration elucidates the mechanism underlying tumor-stromal interactions in different spatiotemporal scales.Scientific reports · 2022Article
- Modeling triple-negative breast cancer heterogeneity: Effects of stromal macrophages, fibroblasts and tumor vasculature.Journal of theoretical biology · 2018Article
- Preface: Computational and experimental methods for biological research: cardiovascular diseases and beyond.Biomedical engineering online · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiogenesis, a process of generation of new blood vessels from the pre-existing vasculature, has been demonstrated to be a basic prerequisite for sustainable growth and proliferation of tumour. Anti-angiogenic treatments show normalization of tumour vasculature and microenvironment at least transiently in both preclinical and clinical settings.
methodsIn this study, we proposed a multi-scale mathematical model to simulate the dynamic changes of tumour microvasculature and microenvironment in response to anti-angiogenic drug endostatin (ES). We incorporated tumour growth, angiogenesis and vessel remodelling at tissue level, by coupling tumour cell phenotypes and endothelial cell behaviour in response to local chemical and haemodynamical microenvironment.
resultsComputational simulation results showed the tumour morphology and growth curves in general tumour progression and following different anti-angiogenic drug strategies. Furthermore, different anti-angiogenic drug strategies were designed to test the influence of ES on tumour growth and morphology. The largest reduction of tumour size was found when ES is injected at simulation time 100, which was concomitant with the emergence of angiogenesis phase.
conclusionThe proposed model not only can predict detailed information of chemicals distribution and vessel remodelling, but also has the potential to specific anti-angiogenic drugs by modifying certain functional modules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.